HC Wainwright Comments on TSE:ONC FY2029 Earnings

Oncolytics Biotech Inc. (TSE:ONC) – Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research report issued to clients and investors on Monday, February 3rd. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of $1.10 per share for the year. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Oncolytics Biotech (TSE:ONC) last issued its quarterly earnings results on Tuesday, November 12th. The company reported C($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of C($0.11) by C($0.01). During the same period in the prior year, the company earned ($0.14) EPS.

Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.

Oncolytics Biotech Price Performance

Shares of ONC stock opened at C$1.05 on Tuesday. The business has a fifty day simple moving average of C$1.23 and a 200 day simple moving average of C$1.36. The company has a market cap of C$80.70 million, a P/E ratio of -2.76 and a beta of 1.35. The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09. Oncolytics Biotech has a twelve month low of C$0.98 and a twelve month high of C$2.08.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.